Dolly S. Chang
Chief Scientific OfficerDr. Dolly S. Chang, M.D., M.P.H., Ph.D., is Chief Scientific Officer of Kodiak Sciences Inc. from August 2024, where she oversees pipeline development and advances transformative therapies for retinal diseases. Dr. Chang joined Kodiak from Genentech, where she held positions of increasing responsibility and directed the early-stage research and clinical ophthalmology pipeline and was responsible for Genentech's early-stage ophthalmology pipeline. Dr. Chang has deep ophthalmology experience in support of Kodiak's early-stage research programs and late-phase Phase 3 programs. She is an accomplished ophthalmologist and biotech leader with extensive experience in clinical development across all stages of ophthalmic drug development. Prior to Kodiak, Dr. Chang was Group Medical Director at Genentech Research and Early Clinical Development (gRED), where she acted as the disease area expert in ophthalmology, co-led the Digital Health Team and provided expertise in corporate development due diligence activities. At Genentech, she steered complex molecule programs across various development stages, championed new therapeutic areas including glaucoma neuroprotection and was pivotal to ocular cell therapy collaboration and development. Dr. Chang earned her M.D. from National Taiwan University and her M.P.H. and Ph.D. from Johns Hopkins University, where she completed her ophthalmology residency. She further specialized with a glaucoma fellowship at Stanford University. Dr. Chang holds a position as Adjunct Clinical Assistant Professor at Stanford University’s Byers Eye Institute, continuing her clinical practice in cataract and glaucoma surgeries, research and mentoring. Dr. Chang also serves on the external scientific advisory board for the Mary Tyler Moore Vision Initiative.
Positions
- Company NameKodiak Sciences Inc.Stock CodeKODPositionChief Scientific OfficerColleagues
- VPVictor PerlrothCo-Founder, Chairman, CEO & President
- JAJohn A. BorgesonExecutive VP, CFO & Secretary
- WTWayne ToChief Technology Officer
- HLHong LiangSenior Vice President of Development
- FJFelix James BakerIndependent Director
- RARobert A. ProfusekLead Independent Director
- CACharles A. BancroftIndependent Director
- BIBassil I. DahiyatIndependent Director
